A medicine made in Bangladesh has cleared another of Europe's strictest markets. Renata PLC has launched amantadine hydrochloride capsules in the Netherlands, a treatment that helps control the symptoms of Parkinson's disease. At home, the same product is sold as Mantadin.

The capsules are made at Renata's Rajendrapur General plant, which is approved under EU good manufacturing practice rules, and shipped in blister packs of 56.

The Netherlands joins a growing European list for the company: the UK, Ireland, France, Denmark, Sweden, Norway, Finland, Portugal and Cyprus.

The business is growing too. In the first quarter of this fiscal year, Renata's revenue rose more than 11% to Tk 1,260 crore and profit rose 36% to Tk 101 crore.

Why it matters: every approval in a regulated market like the Netherlands is proof that Bangladeshi factories can meet the world's toughest quality standards, and it helps patients abroad while bringing export earnings home.